

S10 Table. IC₅₀ values (mean±SD) of *EGFR*-KDD Ba/F3 cell lines against EGFR TKIs

IC ₅₀ (nM)	<i>EGFR</i> -KDD ^{WT a)}	<i>EGFR</i> -KDD ^{D1T b)}	<i>EGFR</i> -KDD ^{D2T c)}	<i>EGFR</i> -KDD ^{BDT d)}
Gefitinib	59.6±19.7	4,332±1,246	8,436±2,360	9,797±2,738
Erlotinib	50.1±17.4	5,089±2,419	> 10,000	8,900±541
Afatinib	< 0.01	219.7±62.8	898.9±277.1	492.3±168.9
Dacomitinib	< 0.01	66.9±38.4	174.7±81.5	446.5±240.8
Osimertinib	0.07±0.04	5.1±0.8	2.7±2.5	12.1±5.3
Lazertinib	0.21±0.2	3.2±2.1	0.2±0.2	6.5±4.7

IC₅₀ values were calculated with cell viability assays. *EGFR*-KDD, epidermal growth factor receptor kinase domain duplication; TKI, tyrosine kinase inhibitor. ^{a)}*EGFR*-KDD^{WT} - *EGFR*-KDD wild type, ^{b)}*EGFR*-KDD^{D1T} - *EGFR*-KDD domain 1 T790M, ^{c)}*EGFR*-KDD^{D2T} - *EGFR*-KDD domain 2 T790M, ^{d)}*EGFR*-KDD^{BDT} - *EGFR*-KDD both domain T790M.